141 related articles for article (PubMed ID: 20513182)
1. Gene expression of proteolytic systems and growth regulators of skeletal muscle in horses with myopathy associated with pituitary pars intermedia dysfunction.
Aleman M; Nieto JE
Am J Vet Res; 2010 Jun; 71(6):664-70. PubMed ID: 20513182
[TBL] [Abstract][Full Text] [Related]
2. Cytokine dysregulation in aged horses and horses with pituitary pars intermedia dysfunction.
McFarlane D; Holbrook TC
J Vet Intern Med; 2008; 22(2):436-42. PubMed ID: 18371032
[TBL] [Abstract][Full Text] [Related]
3. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses.
McFarlane D; Cribb AE
Am J Vet Res; 2005 Dec; 66(12):2065-72. PubMed ID: 16379648
[TBL] [Abstract][Full Text] [Related]
4. Whole-body phenylalanine kinetics and skeletal muscle protein signaling in horses with pituitary pars intermedia dysfunction.
Mastro LM; Adams AA; Urschel KL
Am J Vet Res; 2014 Jul; 75(7):658-67. PubMed ID: 24959733
[TBL] [Abstract][Full Text] [Related]
5. Myopathy in horses with pituitary pars intermedia dysfunction (Cushing's disease).
Aleman M; Watson JL; Williams DC; LeCouteur RA; Nieto JE; Shelton GD
Neuromuscul Disord; 2006 Nov; 16(11):737-44. PubMed ID: 17005399
[TBL] [Abstract][Full Text] [Related]
6. Pituitary pars intermedia dysfunction does not necessarily impair insulin sensitivity in old horses.
Mastro LM; Adams AA; Urschel KL
Domest Anim Endocrinol; 2015 Jan; 50():14-25. PubMed ID: 25240230
[TBL] [Abstract][Full Text] [Related]
7. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
Beech J; Boston R; Lindborg S; Russell GE
J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
[TBL] [Abstract][Full Text] [Related]
8. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction.
McFarlane D; Dybdal N; Donaldson MT; Miller L; Cribb AE
J Neuroendocrinol; 2005 Feb; 17(2):73-80. PubMed ID: 15796757
[TBL] [Abstract][Full Text] [Related]
9. Early laminar events involving endothelial activation in horses with black walnut- induced laminitis.
Loftus JP; Black SJ; Pettigrew A; Abrahamsen EJ; Belknap JK
Am J Vet Res; 2007 Nov; 68(11):1205-11. PubMed ID: 17975975
[TBL] [Abstract][Full Text] [Related]
10. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants.
McFarlane D; Beech J; Cribb A
Domest Anim Endocrinol; 2006 May; 30(4):276-88. PubMed ID: 16115743
[TBL] [Abstract][Full Text] [Related]
11. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses.
Lee ZY; Zylstra R; Haritou SJ
Vet J; 2010 Jul; 185(1):58-61. PubMed ID: 20537574
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effects of age and pituitary pars intermedia dysfunction on corneal sensitivity in horses.
Miller C; Utter ML; Beech J
Am J Vet Res; 2013 Jul; 74(7):1030-5. PubMed ID: 23802675
[TBL] [Abstract][Full Text] [Related]
13. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction.
Miller MA; Pardo ID; Jackson LP; Moore GE; Sojka JE
Vet Pathol; 2008 Jan; 45(1):26-38. PubMed ID: 18192571
[TBL] [Abstract][Full Text] [Related]
14. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses.
Innerå M; Petersen AD; Desjardins DR; Steficek BA; Rosser EJ; Schott HC
Vet Dermatol; 2013 Feb; 24(1):212-7.e46-7. PubMed ID: 23331700
[TBL] [Abstract][Full Text] [Related]
15. Relationships of inflamm-aging with circulating nutrient levels, body composition, age, and pituitary pars intermedia dysfunction in a senior horse population.
Siard-Altman MH; Harris PA; Moffett-Krotky AD; Ireland JL; Betancourt A; Barker VD; McMurry KE; Reedy SE; Adams AA
Vet Immunol Immunopathol; 2020 Mar; 221():110013. PubMed ID: 32058159
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin expression in muscle from horses with polysaccharide storage myopathy.
Valentine BA; Flint TH; Fischer KA
Vet Pathol; 2006 May; 43(3):270-5. PubMed ID: 16672573
[TBL] [Abstract][Full Text] [Related]
17. Time course of proteolytic, cytokine, and myostatin gene expression after acute exercise in human skeletal muscle.
Louis E; Raue U; Yang Y; Jemiolo B; Trappe S
J Appl Physiol (1985); 2007 Nov; 103(5):1744-51. PubMed ID: 17823296
[TBL] [Abstract][Full Text] [Related]
18. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
Rendle DI; Litchfield E; Heller J; Hughes KJ
Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of plasma ACTH, alpha-melanocyte-stimulating hormone, and insulin concentrations during various photoperiods in clinically normal horses and ponies and those with pituitary pars intermedia dysfunction.
Beech J; Boston RC; McFarlane D; Lindborg S
J Am Vet Med Assoc; 2009 Sep; 235(6):715-22. PubMed ID: 19751169
[TBL] [Abstract][Full Text] [Related]
20. Muscle wasting in a rat model of long-lasting sepsis results from the activation of lysosomal, Ca2+ -activated, and ubiquitin-proteasome proteolytic pathways.
Voisin L; Breuillé D; Combaret L; Pouyet C; Taillandier D; Aurousseau E; Obled C; Attaix D
J Clin Invest; 1996 Apr; 97(7):1610-7. PubMed ID: 8601625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
